Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival

Journal of Laboratory and Clinical Medicine

Volumn 142, Issue 1, 2003, Pages 46-51

  Raffel, Jennifer ^a   Bhattacharyya, Achyut K ^a   Gallegos, Alfred ^a   Cui, Haiyan ^a   Einspahr, Janine G ^a   Alberts, David S ^a   Powis, Garth ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THIOREDOXIN; THIOREDOXIN 1; UNCLASSIFIED DRUG;

ADENOMATOUS POLYP; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COLON CARCINOGENESIS; COLON MUCOSA; COLON POLYP; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0042991494     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(03)00068-4     Document Type: Article

References (32)

1. Powis G, Montfort WR. Properties and biological activities of thioredoxins. Ann Rev Pharm Toxicol 2001;41:261-95.
2. Wei SJ, Botero A, Hirota K, Bradbury CM, Markovina S, Lazlo A, et al. Thioredoxin nuclear translocation and interaction with redox factor-1 activates the activator protein-1 transcription factor in response to ionizing radiation. Cancer Res 2000;60:6688-95.
3. Gasdaska PY, Oblong JE, Cotgreave IA, Powis G. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): Thioredoxin mRNA is elevated in some human tumors. Biochim Biophys Acta 1994;1218:292-6.
4. Spyrou G, Enmark E, Miranda-Vizuete A, Gustafsson J-Å. Cloning and expression of a novel mammalian thioredoxin. J Biol Chem 1997;272:2936-41.
5. Mustacich D, Powis G. Thioredoxin reductase. Biochem J 2000;346:1-8.
6. Grippo JF, Tienrungroj W, Dahmer MK, Housley PR, Pratt WB. Evidence that the endogenous heat-stable glucocorticoid receptor-activating factor is thioredoxin. J Biol Chem 1983;258:13658-64.
7. Qin J, Clore GM, Kennedy WP, Hutch JR, Gronenborn AM. Solution structure of human thioredoxin in a mixed disulfide intermediate complex with its target peptide from the transcription factor NF-kappa B. Structure 1994;3:289-97.
8. Ueno M, Masutani H, Jun Arai R, Yamauchi A, Hirota K, Sakai T, et al. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 2000;274:35809-15.
9. Abate C, Patel L, Rauscher FJ III, Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science 1990;249:1157-61.
10. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998;17:2596-606.
11. Watson JA, Rumsby MG, Wolowacz RG. Phage display identifies thioredoxin and superoxide dismutase as novel protein kinase C-interacting proteins: thioredoxin inhibits protein kinase C-mediated phosphorylation of histone. Biochem J 1999;343:301-5.
12. Powis G, Meuillet E, Berggren M, Williams R, Coon A. The tumor suppressor PTEN is inhibited by binding of thioredoxin-1 in a redox dependent manner. Proc Am Assoc Cancer Res 2001;42:2247.
13. Baker A, Payne CM, Briehl MM, Powis G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res 1997;57:5162-7.
14. Freemerman AJ, Powis G. A redox-inactive thioredoxin reduces growth and enhances apoptosis in WEH17.2 cells. Biochem Biophys Res Commun 2000;274:136-41.
15. Gallegos A, Gasdaska JR, Taylor CW, Paine-Murrieta GD, Goodman D, Gasdaska PY, et al. Transfection with human thioredoxin increases cell proliferation and a dominant negative mutant thioredoxin reverses the transformed phenotype of breast cancer cells. Cancer Res 1996;56:5765-70.
16. Fujii S, Nanbu Y, Nonogaki H, Koniski I, Mori T, Masutani H, et al. Coexpression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium. Cancer 1991;68:1583-91.
17. Soini Y, Kahlos K, Napankangas U, Kaarteenaho-Wiik R, Saily M, Koistinen P, et al. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 2001;7:1750-7.
18. Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, Sivridis E, et al. Thioredoxin expression associates with lymph node status and prognosis in early operable non small cell lung cancer (NSCLC). Clin Cancer Res 2001;7:3087-91.
19. Kawahara N, Tanaka T, Yokomizo A, Nanri H, Ono M, Wada M, et al. Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res 1996;56:5330-3.
20. Nakamura H, Masutani H, Tagaya Y, Yamauchi A, Inamoto T, Nanbu Y, et al. Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. Cancer 1992;69:2091-7.
21. Wakita H, Yodoi J, Masutani H, Toda K, Takigawa M. Immunohistochemical distribution of adult T-cell leukemia-derived factor/thioredoxin in epithelial components of normal and pathologic human skin conditions. J Invest Dermatol 1992;99:101-7.
22. Nakamura H, Bai J, Nishinaka Y, Ueda S, Sasada T, Ohshio G, et al. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev 2000;24:53-60.
23. Grogan TM, Fenoglio-Prieser C, Zeheb R, Bellamy W, Frutiger Y, Vela E, et al. Thioredoxin, a puntative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol 2000;31:475-81.
24. Alberts DS, Martinez ME, Roe DJ, Guillen-Rodriguez JM, Marshall JR, van Leeuwen JB, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. New Engl J Med 2000;342:1156-62.
25. Yang J, Hanley J, Yu Y, Berney C, Russell P, Crowe P. In vivo overexpression of c-erbB-2 oncoprotein in xenografts of mice implanted with human colon cancer lines. Anticancer Res 1997;17:3463-8.
26. Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J, Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res 1996;16:3459-66.
27. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, et al. Gene expression profiles in normal and cancer cells. Science 1997;276:1268-72.
28. McLeod HL, Murray GI. Tumour markers of prognosis in colorectal cancer. Br J Cancer 1999;79:191-203.
29. Hamilton SR. Colon cancer testing and screening. Arch Patrol Lab Med 1999;123:1027-9.
30. Kulesz-Martin M. Molecular markers for colon cancer: where do we go from here? Cancer Invest 2000;18:287-8.
31. Kirkpatrick DL, Watson S, Kunkel M, Fletcher S, Ulhaq S, Powis G. Parallel syntheses of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents. Anticancer Drug Des 2000;14:421-32.
32. Powis G, Kirkpatric DL, Angulo M, Gasdaska JR, Powell MB, Salmon SE, et al. Thioredoxin redox signaling: a novel target for anticancer drug development. Anticancer Drugs 1996;7(suppl 3):121-6.